Senthil Kumar discusses the KEYNOTE-590 study on advanced esophageal cancer
Senthil Kumar, Medical Oncologist at Red Hills Chennai, shared a post on X about a paper by Manish Shah et al. published in Journal of Clinical Oncology:
“First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
KEYNOTE-590 Study: 5-Year Outcomes of Pembrolizumab and Chemotherapy for Advanced Esophageal Cancer.
Participants:
749 patients randomized (Pembrolizumab + Chemo: 373, Placebo + Chemo: 376).
Key Findings:
Median Overall Survival (OS):
Pembrolizumab + Chemo: 12.3 months
Placebo + Chemo: 9.8 months
5-Year OS Rate:
Pembrolizumab + Chemo: 10.6%
Placebo + Chemo: 3.0%
Median Progression-Free Survival (PFS):
Pembrolizumab + Chemo: 6.3 months
Placebo + Chemo: 5.8 months
5-Year PFS Rate:
Pembrolizumab + Chemo: 5.5%
Placebo + Chemo: 0%
Efficacy in Specific Populations:
ESCC and CPS ≥10:
5-Year OS Rate: 13.8% vs 3.7%
Median Duration of Response (DOR): 10.4 months vs 4.4 months
Safety:
Grade 3-5 Treatment-Related AEs:
Pembrolizumab + Chemo: 71.9%
Placebo + Chemo: 67.6%
Deaths Due to AEs:
Pembrolizumab + Chemo: 2.4%
Placebo + Chemo: 1.4%
Conclusion:
Pembrolizumab + Chemo shows durable efficacy, no new safety signals, remains a first line in advanced esophageal cancer.
The first line regimens in advanced esophageal/OGJ cancers.”
Authors: Manish Shah, Jong-Mu Sun, Lin Shen, Pooja Bhagia, Jean-Philippe Metges et al.
More posts featuring Senthil Kumar.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023